First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.

Androgen Antagonists Castration Docetaxel / therapeutic use Humans Male Prospective Studies Prostatic Neoplasms / drug therapy Prostatic Neoplasms, Castration-Resistant / drug therapy
Abiraterone Apalutamide Castration-sensitive prostate cancer Enzalutamide

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 18 10 2020
revised: 26 11 2020
accepted: 30 11 2020
pubmed: 15 12 2020
medline: 23 1 2021
entrez: 14 12 2020
Statut: ppublish

Résumé

Although both docetaxel and androgen-receptor-axis-targeted (ARAT) agents have yielded survival improvements in combination with androgen deprivation therapy (ADT) compared to ADT alone in metastatic castration-sensitive prostate cancer (mCSPC) patients, the optimal therapeutic choice remains to be established. We analyzed estimates of the hazard ratios for death (OS-HRs) in patients treated in the first-line setting enrolled in the GETUG-AFU15, CHAARTED, STAMPEDE, LATITUDE, ENZAMET, and TITAN trials. Overall, men with mCSPC receiving ADT with vs. without either an ARAT agent or docetaxel as first-line systemic therapy showed a pooled OS-HR of 0.69 (95 % CI: 0.61-0.78), with significant heterogeneity (p = 0.045, I

Identifiants

DOI: 10.1016/j.critrevonc.2020.103198 PMID: 33316417
pubmed: 33316417
pii: S1040-8428(20)30334-6
doi: 10.1016/j.critrevonc.2020.103198
pii:
doi:

Substances chimiques

Androgen Antagonists 0
Docetaxel 15H5577CQD

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

103198

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Matteo Ferro (M)

Division of Urology, European Institute of Oncology-IRCCS, Milan, Italy.

Giuseppe Lucarelli (G)

Department of Emergency and Organ Transplantation, Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.

Felice Crocetto (F)

Department of Neurosciences, Human Reproduction and Odontostomatology, University of Naples Federico II, Naples, Italy.

Pasquale Dolce (P)

Department of Public Health, Federico II University of Naples, Naples, Italy.

Antonio Verde (A)

Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.

Evelina La Civita (E)

Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.

Silvia Zappavigna (S)

Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy.

Ottavio de Cobelli (O)

Division of Urology, European Institute of Oncology-IRCCS, Milan, Italy.

Giuseppe Di Lorenzo (G)

Oncology Unit, Hospital "Andrea Tortora," ASL Salerno, Pagani, Italy; Department of Medicine and Health Sciences "Vincenzo Tiberio", University of Molise, Campobasso, Italy.

Bianca Arianna Facchini (BA)

Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy.

Luca Scafuri (L)

Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.

Livia Onofrio (L)

Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.

Angelo Porreca (A)

Department of Urology, Abano Terme Hospital, Padua, Italy.

Gian Maria Busetto (GM)

Department of Urology, Sapienza University of Rome, Roma, Italy.

Guru Sonpavde (G)

Genitourinary Oncology Section, Dana Farber Cancer Institute, Boston, MA, United States.

Michele Caraglia (M)

Department of Precision Medicine, University of Campania "L. Vanvitelli", Naples, Italy; Biogem Scarl, Institute of Genetic Research, Laboratory of Precision and Molecular Oncology, Ariano Irpino, Avellino, Italy.

Michele Klain (M)

Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.

Daniela Terracciano (D)

Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.

Sabino De Placido (S)

Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy; Regional Reference Center for Rare Tumors, Department of Oncology and Hematology, AOU Federico II of Naples, Naples, Italy.

Carlo Buonerba (C)

Regional Reference Center for Rare Tumors, Department of Oncology and Hematology, AOU Federico II of Naples, Naples, Italy; Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, 80055, Portici (Na), Italy. Electronic address: carlo.buonerba@unina.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Antagonistes des androgènes › First-line systemic therapy for metastatic...
questionsmedicales.fr › Procédures de chirurgie opératoire › Procédures de chirurgie urogénitale › Castration › First-line systemic therapy for metastatic...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Terpènes › Diterpènes › Taxoïdes › Docetaxel › First-line systemic therapy for metastatic...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › First-line systemic therapy for metastatic...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › First-line systemic therapy for metastatic...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › First-line systemic therapy for metastatic...
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Tumeurs prostatiques résistantes à la castration › First-line systemic therapy for metastatic...